NEW YORK (GenomeWeb) – Repositive and AstraZeneca this week named the inaugural members of the PDX Consortium, a group that was set up with the aim of developing a collaborative, pre-competitive resource of molecular data from patient-derived xenografts (PDXs) for use in oncology research. Inaugural members include AstraZeneca, Boehringer Ingelheim, Merck Group, Xentech, Xenopat, and Horizon Discovery.
Danaher announced this week that its board of directors has approved a regular quarterly dividend of $.13 per share, payable on Jan. 27, 2017, to holders of record on Dec. 30, 2016.
Cancer Genetics said this week that it has been added to Merck's list of national reference laboratories offering the PD-L1 22C3 pharmDx immunohistochemistry (IHC) assay as a companion diagnostic to test for PD-L1 in non-small cell lung cancer before treatment with pembrolizumab (Keytruda). Cancer Genetics said it now offers all the available US Food and Drug Administration-approved companion diagnostics for PD-L1 testing across several cancer indications.
In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on the GenomeWeb site.